Xilio raises $95M to take twists on Yervoy and IL-2 into clinic

Xilio raises $95M to take twists on Yervoy and IL-2 into clinic

Source: 
Fierce Biotech
snippet: 

Xilio Therapeutics has raised $95 million to take IL-2 and CTLA-4 immunotherapies into clinical trials. The series C positions Xilio to provide early clinical validation of anti-cancer agents that are designed to remain inactive until they reach tumors.